title: Recovery from deepening of the upper eyelid sulcus after switching from bimatoprost to latanoprost.
abstract: OBJECTIVE
  Although useful for reducing intraocular pressure (IOP), bimatoprost (BIM) can cause deepening of the upper eyelid sulcus (DUES), one of the symptoms of prostaglandin-associated periorbitopathy (PAP). We investigated recovery from BIM-induced DUES after switching treatment to latanoprost (LAT).
  
  
  METHODS
  Prospective, observer-masked, open-label study.
  
  
  METHODS
  Twenty-five Japanese patients suffering from primary open-angle glaucoma treated with LAT in both eyes for longer than 6 months and requiring further IOP reduction were prospectively enrolled in the study. During the first 6 months after the switch to BIM, 15 of the 25 patients (60 %) developed DUES. Among these patients, 13 were switched back to LAT and re-examined for DUES at 2-month intervals for an additional 6 months.
  
  
  RESULTS
  Two months after the switch back to LAT, for 11 of the 13 patients (85 %) the DUES symptoms had either decreased or disappeared, and this was maintained for at least 6 months. During this time, 6 of 8 patients (75 %) subjectively positive for DUES self-reported a decrease in DUES.
  
  
  CONCLUSIONS
  Although DUES is a frequent side effect of treatment with BIM, switching to LAT may reverse the condition for most patients.
authors.affiliation: Department of Ophthalmology, Tokyo Metropolitan Geriatric Hospital, 35-2 Sakaecho, Itabashi, Tokyo, Japan. reisakata-tky@umin.ac.jp
authors.forename: Rei
authors.initials: R
authors.lastname: Sakata
authors.forename: Shiroaki
authors.initials: S
authors.lastname: Shirato
authors.forename: Kazunori
authors.initials: K
authors.lastname: Miyata
authors.forename: Makoto
authors.initials: M
authors.lastname: Aihara
mesh_terms: D000328:Adult; D000368:Aged; D000577:Amides / Q000009:adverse effects*; D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000069580:Bimatoprost; D003008:Cloprostenol / Q000009:adverse effects / Q000031:analogs & derivatives*; D057915:Drug Substitution; D005141:Eyelid Diseases / Q000139:chemically induced / Q000503:physiopathology*; D005143:Eyelids / Q000187:drug effects / Q000503:physiopathology*; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*; D020127:Recovery of Function
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; D000069580:Bimatoprost